Search

A 33-year-old female, Fitzpatrick IV phototype, developed varicella zoster eruption over the ophthalmic dermatome of the right trigeminal nerve, confirmed through Polymerase Chain Reaction, 4 weeks after recovering from COVID-19 disease. After the resolution of the acute manifestations, she developed significant atrophic scars on the forehead, about 2 mm deep, with marked post-inflammatory hyperpigmentation. She came to our clinic looking for treatment, as the scars caused significant psychological distress. We decided for a combination treatment with Erbium:glass 1540 nm non-ablative laser and 755 nm Alexandrite picosecond laser. After 16 weeks of starting treatment, significant improvement was observed, with complete resolution of the hyperpigmentation and overall improvement in the atrophic scar. No complications occurred during the treatment period. This strategy may be an effective and safe option to treat these lesions, which may be increasingly found in young individuals after COVID-19 disease or SARS-CoV-2 vaccination, even in darker skin phototypes.

We are entering a new stage of the severe acute respiratory syndrome coronavirus 2 pandemic with the initiation of large-scale vaccination programs globally. In these circumstances, even rare adverse effects of vaccines may be encountered more often, if millions of people are to be vaccinated in a short period. Vaccination has the potential for causing cutaneous adverse effects. Thus, it is paramount that dermatologists worldwide are acquainted with the possible skin reaction patterns to the coming vaccines. Herein, we conduct a review to discuss the most frequent cutaneous adverse effects of vaccines and their management, with a particular focus on the expected adverse reactions for the coming severe acute respiratory syndrome coronavirus 2 vaccines, such as local reactions, as well as immediate- and delayed-type hypersensitivity reactions, including erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrosis, serum sickness-like reactions, and vasculitides. We also discuss the yet unanswered questions on vaccines for which we may soon be asked to provide an expert opinion., Competing Interests: The authors have no funding or conflicts of interest to declare., (Copyright © 2021 American Contact Dermatitis Society. All Rights Reserved.)

In addition, all studies demonstrating clinical benefit of these drugs in patients with COVID-19 patients were conducted in unvaccinated individuals and most in unimmunized individuals with no previous infection. Cutaneous adverse reactions to the new oral antiviral drugs against SARS-CoV-2 Currently, there are two oral antivirals directed to SARS-CoV-2: molnupiravir (Lagevrio SP ® sp ), which induces an antiviral effect via viral error catastrophe, and nirmatrelvir-ritonavir (Paxlovid™) (nirmatrelvir inhibits an enzyme needed for coronavirus replication and ritonavir decreases metabolism of nirmatrelvir, maintaining its antiviral activity at higher levels). [Extracted from the article]

We hypothesize that antiretroviral therapy in the context of HIV infection or Pre-Exposure Prophylaxis (PrEP) against HIV infection may offer some degree of protection against, at least, severe forms of SARS-CoV-2 infection. Even in a reference article where caution is advised when considering HIV-infected individuals to have lower risk of severe COVID-19, we can see that the patients undergoing antiretroviral treatment with TDF/FTC did not present poor outcomes [[9]]. We, thus, propose that further investigation should be carried to investigate the potential merits of common antiretrovirals in the treatment of early COVID-19 infection, or even as PrEP for this infection. [Extracted from the article]

Dear Editor, This report analyzes the case of a 63-year-old Caucasian male, Fitzpatrick III phototype, who was admitted to the Intensive Care Unit (ICU) due to a severe coronavirus disease 2019 (COVID-19) pneumonia. Seborrheic dermatitis (SD) was diagnosed, and the patient was prescribed hydrocortisone cream bid, with complete resolution of the dermatosis after 7 days. When assessing patients with I de novo i onset of severe SD, or significant exacerbation of a previously mild SD, physicians should consider the possibility of underlying COVID-19 as they do for HIV infection. [Extracted from the article]

The article focuses on impacts of isolation measures against SARS‑CoV‑2 infection on sexual health. Topics include the physical distancing and social isolation may directly impact both the physical and psychological health of individuals, the area may see significant ancillary ramifications of COVID-19 pertains to sexual health, and the social isolation and the closure of leisure venues may significantly reduce the opportunity for casual sexual encounters.

Inpatient care for dermatological patients during SARS-CoV-2 - a case report from Portugal Dear Editor, The recent SARS-CoV-2 pandemic has put a significant strain on dermatological practice. The change in facilities allows dermatological patients to be diverted to parallel circuits away from the epicenter of SARS-CoV-2. [Extracted from the article]